<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869726</url>
  </required_header>
  <id_info>
    <org_study_id>12788</org_study_id>
    <secondary_id>I3E-BM-MSAB</secondary_id>
    <secondary_id>MBP8298-01</secondary_id>
    <nct_id>NCT00869726</nct_id>
  </id_info>
  <brief_title>A Study for Patients With Secondary Progressive Multiple Sclerosis</brief_title>
  <acronym>MAESTRO-01</acronym>
  <official_title>A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMS Technology Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MBP8298 is effective and safe in the
      treatment secondary progressive multiple sclerosis.

      Dirucotide is generic name for MBP8298.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS).</measure>
    <time_frame>baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>degree of change in EDSS</measure>
    <time_frame>baseline, 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Atrophy by MRI</measure>
    <time_frame>baseline, 12mos, 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity analysis of T2 and Gadolinium enhancing lesions</measure>
    <time_frame>12mos and 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion burden</measure>
    <time_frame>12mos and 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of change in MS Functional Composite Index (MSFC)</measure>
    <time_frame>baseline, 3mos, 6mos, 9mos, 12mos, 15mos, 18mos, 21mos, 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rates</measure>
    <time_frame>baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by Short Form 36 (SF-36) or MSQoL54</measure>
    <time_frame>baseline, 6mos, 12mos, 18mos, 24mos</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">596</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Dirucotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dirucotide</intervention_name>
    <description>500mg, intravenous, dosed once every six months for 18 months</description>
    <arm_group_label>Dirucotide</arm_group_label>
    <other_name>MBP8298</other_name>
    <other_name>LY2820671</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous, once every six months for 18 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of SPMS

          -  Absence of relapse in the 3mos prior to baseline

          -  EDSS of 3.5 - 6.5

          -  Pyramidal or Cerebellar FSS greater than or equal to 3

          -  A cohort of 100 HLA DR2/4 negative patients is required. Once enrollment to this
             cohort is complete, all further patients are required to be HLA DR2/4 positive.

          -  Informed consent

          -  Subject reliability and compliance

        Exclusion Criteria:

          -  Diagnosis of Primary Progressive MS

          -  Subjects have previously received MBP8298

          -  Recent history of malignancy, with the exclusion on basal cell carcinoma.

          -  Steroid therapy within 30 days prior to first study specific procedure or any other
             treatment known to be used for putative or experimental MS treatment

          -  Therapy with beta-interferon, glatiramer acetate within 3 mos or mitoxantrone,
             cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating or
             immunosuppressive drugs including recombinant or non-recombinant cytokines or plasma
             exchange within 6 mos prior to performance of the first study-specific test, with the
             exception of corticosteroids or ACTH for relapse treatment.

          -  Initiation or discontinuation of therapy with 4-AP or 3,4-DAP at any time during the
             study period.

          -  History of anaphylactic/anaphlactoid reactions to glatiramer acetate

          -  Abnormal lab values at the Screening Visit deemed by the Investigator to be clinically
             significant

          -  Known allergy to Gadolinium-DTPA

          -  Treatment at any time with Cladribine, total lymphoid irradiation, monoclonal antibody
             treatment

          -  Treatment at any time wtih an altered peptide ligand

          -  Any conditions that could interfere with the performance of study specific procedures
             e.g.MRI

          -  Previous randomization to this study

          -  Known positivity for HIV, Hepatitis B, or Hepatitis C

          -  Participation in any other non-MS clinical trial within 30 days prior to performance
             of the first study specific test or any investigational therapy in the past 6 mos.

          -  Females who are breast feeding, pregnant or not using a medically approved method of
             contraception regularly

          -  Known or suspected current or past alcohol or drug abuse (within the last year)

          -  Any medical, psychiatric or other condition that could result in a subject not being
             able to give fully informed consent, or to comply with the protocol requirements

          -  Any other condition that, in the investigator's opinion, makes the subject unsuitable
             for participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Michaels Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Turku Kuvantaminen</name>
      <address>
        <city>Turku</city>
        <zip>20101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine Universitaets</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vecmilgravis Hospital</name>
      <address>
        <city>Riga</city>
        <zip>1015</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maaslandziekenhuis</name>
      <address>
        <city>Sittard</city>
        <zip>6131 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walton Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L97LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <disposition_first_submitted>May 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>May 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2010</disposition_first_posted>
  <last_update_submitted>May 27, 2010</last_update_submitted>
  <last_update_submitted_qc>May 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

